Barr Launches DDAVP Generic With 180-Day Exclusivity
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA approves Barr’s ANDA for Sanofi-Aventis’ bed-wetting therapy DDAVP. Approval comes five months after Barr prevailed in a patent dispute with DDAVP manufacturer Ferring.